Risk stratification of postoperative cardiopulmonary toxicity after trimodality therapy for esophageal cancer
Roman O. Kowalchuk(Mayo Clinic in Arizona), Kenneth W. Merrell(Mayo Clinic), Michael D. Chuong(Baptist Hospital of Miami), Harry H. Yoon(Mayo Clinic), Christopher L. Hallemeier(Mayo Clinic in Arizona), Matthew J. Ferris(University of Maryland, Baltimore), Dennis A. Wigle(Mayo Clinic), Michael G. Haddock(Mayo Clinic in Arizona), Steven H. Lin(The University of Texas MD Anderson Cancer Center), Krishan R. Jethwa(Mayo Clinic), Dawn Owen(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Lindsay K. Morris(WinnMed), Grant M. Spears(Mayo Clinic in Florida)
Cited by 4
Related Papers
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
|JAMA Oncology|2018|1.8k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|746
Neuropeptide S
|Neuron|2004|516